PROKR2

prokineticin receptor 2, the group of Prokineticin receptors

Basic information

Region (hg38): 20:5299218-5316954

Previous symbols: [ "GPR73L1", "KAL3" ]

Links

ENSG00000101292NCBI:128674OMIM:607123HGNC:15836Uniprot:Q8NFJ6AlphaFoldGenCCjaxSfariGnomADPubmedClinVar

Phenotypes

GenCC

Source: genCC

  • hypogonadotropic hypogonadism 3 with or without anosmia (Definitive), mode of inheritance: AD
  • hypogonadotropic hypogonadism 3 with or without anosmia (Strong), mode of inheritance: AD
  • septooptic dysplasia (Supportive), mode of inheritance: AD
  • Kallmann syndrome (Supportive), mode of inheritance: AD
  • hypogonadotropic hypogonadism (Supportive), mode of inheritance: AD
  • hypogonadotropic hypogonadism 3 with or without anosmia (Strong), mode of inheritance: AD
  • hypogonadotropic hypogonadism 3 with or without anosmia (Definitive), mode of inheritance: AD

Clinical Genomic Database

Source: CGD

ConditionInheritanceIntervention CategoriesIntervention/Rationale Manifestation CategoriesReferences
Hypogonadotropic hypogonadism 3 with or without anosmiaAD/AREndocrineIn Hypogonadotropic hypogonadism, surveillance in adolescence related to sexual maturation is indicated, as is monitoring of bone mineral density in order to allow early detection and treatment of disease; In order to induce and maintain secondary sex characteristics, gradually increasing doses of gonadal steroids (females: estrogen/progestin; males: testosterone/hCG) can be beneficial; Related to fertility, endocrinologic therapy (females: recombinant hCG or pulsatile GnRH therapy; males: hCG/HMG/recombinant FSH or pulsatile GnRH therapy) may be effective, though IVF may be requiredCraniofacial; Endocrine; Neurologic17054399; 20301509
Digenic inheritance (with KAL1) has been reported

ClinVar

This is a list of variants' phenotypes submitted to ClinVar and linked to the PROKR2 gene.

  • not provided (3 variants)
  • Hypogonadotropic hypogonadism 3 with or without anosmia (1 variants)

Variants pathogenicity by type

Statistics on ClinVar variants can assist in determining whether a specific variant type in the PROKR2 gene is commonly pathogenic or not.

In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.

Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.

Variant type Pathogenic Likely pathogenic VUS Likely benign Benign Sum
synonymous
3
clinvar
26
clinvar
6
clinvar
35
missense
1
clinvar
3
clinvar
54
clinvar
6
clinvar
64
nonsense
2
clinvar
1
clinvar
3
start loss
0
frameshift
2
clinvar
2
inframe indel
1
clinvar
1
splice donor/acceptor (+/-2bp)
1
clinvar
1
splice region
0
non coding
2
clinvar
13
clinvar
15
Total 4 5 59 34 19

Highest pathogenic variant AF is 0.0000854

Variants in PROKR2

This is a list of pathogenic ClinVar variants found in the PROKR2 region.

You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.

Position Type Phenotype Significance ClinVar
20-5301912-C-T Benign (Aug 30, 2018)1250628
20-5301913-A-G Benign (Jun 26, 2018)1232229
20-5301954-T-C Benign (Nov 05, 2018)1240794
20-5301973-A-T Benign (Jun 26, 2018)1291545
20-5302040-T-A not specified Uncertain significance (May 31, 2023)2506104
20-5302066-C-T Uncertain significance (Oct 07, 2023)2764349
20-5302073-G-T Hypogonadotropic hypogonadism 3 with or without anosmia • not specified Benign (Jan 29, 2024)338851
20-5302075-T-C Uncertain significance (May 08, 2022)1907206
20-5302082-C-A Uncertain significance (Jun 17, 2021)1430101
20-5302084-C-G Hypogonadotropic hypogonadism 3 with or without anosmia • not specified Conflicting classifications of pathogenicity (May 18, 2023)895676
20-5302084-C-T Hypogonadotropic hypogonadism 3 with or without anosmia Uncertain significance (Mar 25, 2022)895677
20-5302085-G-A Hypogonadotropic hypogonadism 3 with or without anosmia • not specified Benign (Jan 29, 2024)338852
20-5302126-G-A PROKR2-related disorder Uncertain significance (Apr 06, 2023)2886691
20-5302137-C-T not specified Conflicting classifications of pathogenicity (Aug 25, 2023)1012475
20-5302139-C-T Uncertain significance (Dec 05, 2023)2886479
20-5302143-T-G Hypogonadotropic hypogonadism 3 with or without anosmia Uncertain significance (Jan 13, 2018)895678
20-5302145-C-T Hypogonadotropic hypogonadism 3 with or without anosmia Likely benign (Feb 15, 2022)715326
20-5302153-T-G Hypogonadotropic hypogonadism 3 with or without anosmia Uncertain significance (Dec 13, 2021)1050416
20-5302176-G-C Hypogonadotropic hypogonadism 3 with or without anosmia • Amenorrhea Conflicting classifications of pathogenicity (Mar 08, 2021)1184526
20-5302190-C-T Hypogonadotropic hypogonadism 3 with or without anosmia • PROKR2-related disorder Benign (Jan 13, 2024)338853
20-5302191-G-A Uncertain significance (Oct 24, 2022)1954618
20-5302195-C-A Uncertain significance (Aug 01, 2024)3342196
20-5302195-C-G PROKR2-related disorder Uncertain significance (Apr 15, 2024)3357487
20-5302195-C-T not specified Uncertain significance (Dec 17, 2023)1874771
20-5302204-C-T not specified • Hypogonadotropic hypogonadism 3 with or without anosmia Benign/Likely benign (Jan 29, 2024)338854

GnomAD

Source: gnomAD

GeneTypeBio TypeTranscript Coding Exons Length
PROKR2protein_codingprotein_codingENST00000546004 215062
pLI Probability
LOF Intolerant
pRec Probability
LOF Recessive
Individuals with
no LOFs
Individuals with
Homozygous LOFs
Individuals with
Heterozygous LOFs
Defined p
0.000002440.3061257050431257480.000171
Z-Score Observed Expected Observed/Expected Mutation Rate Total Possible in Transcript
Missense-0.1192382331.020.00001582543
Missense in Polyphen6172.4960.84142766
Synonymous-0.90910694.71.120.00000681774
Loss of Function0.25099.850.9144.33e-7120

LoF frequencies by population

EthnicitySum of pLOFs p
African & African-American0.0004410.000441
Ashkenazi Jewish0.000.00
East Asian0.00005440.0000544
Finnish0.000.00
European (Non-Finnish)0.0002200.000220
Middle Eastern0.00005440.0000544
South Asian0.0001310.000131
Other0.000.00

dbNSFP

Source: dbNSFP

Function
FUNCTION: Receptor for prokineticin 2. Exclusively coupled to the G(q) subclass of heteromeric G proteins. Activation leads to mobilization of calcium, stimulation of phosphoinositide turnover and activation of p44/p42 mitogen-activated protein kinase.;
Pathway
GPCRs, Other;Signaling by GPCR;Signal Transduction;Peptide ligand-binding receptors;Class A/1 (Rhodopsin-like receptors);GPCR ligand binding;G alpha (q) signalling events;GPCR downstream signalling (Consensus)

Recessive Scores

pRec
0.134

Intolerance Scores

loftool
0.504
rvis_EVS
-0.22
rvis_percentile_EVS
37.54

Haploinsufficiency Scores

pHI
0.168
hipred
N
hipred_score
0.296
ghis
0.417

Essentials

essential_gene_CRISPR
N
essential_gene_CRISPR2
N
essential_gene_gene_trap
gene_indispensability_pred
N
gene_indispensability_score
0.156

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium

Mouse Genome Informatics

Gene name
Prokr2
Phenotype
homeostasis/metabolism phenotype; cellular phenotype; endocrine/exocrine gland phenotype; growth/size/body region phenotype; integument phenotype (the observable morphological and physiological characteristics of the skin and its associated structures, such as the hair, nails, sweat glands, sebaceous glands and other secretory glands that are manifested through development and lifespan); nervous system phenotype (the observable morphological and physiological characteristics of the extensive, intricate network of electochemical structures in the body that is comprised of the brain, spinal cord, nerves, ganglia and parts of the receptor organs that are manifested through development and lifespan); reproductive system phenotype; mortality/aging (the observable characteristics related to the ability of a mammalian organism to live and age that are manifested throughout development and life span); behavior/neurological phenotype (the observable actions or reactions of mammalian organisms that are manifested through development and lifespan);

Gene ontology

Biological process
G protein-coupled receptor signaling pathway;neuropeptide signaling pathway;circadian rhythm
Cellular component
plasma membrane;integral component of plasma membrane
Molecular function
G protein-coupled receptor activity;neuropeptide Y receptor activity